BrainsWay Deep TMS - Innovative, Noninvasive Treatment

Elevate Mental Health Treatment with BrainsWay Deep TMS™

BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression.  Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Treatment in Patients Between the Ages of 68 and 86.  Learn More.

About Us

Who is BrainsWay?

A global medical technology company, BrainsWay focuses on developing cutting-edge medical devices that help advance the field of mental healthcare. Our advanced flagship technology of Deep Transcranial Magnetic Stimulation (Deep TMS™) is expanding the treatment of mental health beyond what was thought possible.

Deep TMS treatment has been proven to offer significant results by directly stimulating deeper and broader areas of the brain, effectively treating conditions such as depression, anxious depression, late-life depression, obsessive-compulsive disorder, and smoking addiction.

With numerous clinical studies and a growing number of patients and healthcare providers attesting to its success, BrainsWay Deep TMS is boldly advancing the treatment of mental health disorders.

Learn more about TMS


Transforming Late-Life Depression with Deep TMS: Insights and Evidence
Explore BrainsWay’s FDA-clearance to treat late-life depression, focusing on clinical evidence and unique design benefits for elderly patients


What do we treat?

BrainsWay’s innovative treatment has been proven beneficial in treating a number of mental health conditions, thanks to its safety and efficacy.

For Patients
Check out all of our treatments that we offer to help you be the best you can be.
For Healthcare Providers
We can help healthcare providers with our clinically proven technology.

Featured Treatments

Major Depressive Disorder (MDD) treatment
BrainsWay’s safe and effective Deep TMS is FDA-cleared to treat major depressive disorder (depression), offering patients a better quality of life.

Anxious Depression treatment
Deep TMS can safely and effectively reduce comorbid anxiety symptoms in adult patients with depression.

Late-Life Depression treatment
Our recent FDA clearance demonstrates the reduction of depression symptoms among elderly patients, aged 68-86.

Obsessive-Compulsive Disorder (OCD) treatment
BrainsWay introduces the first FDA-cleared (de novo) noninvasive medical device for the treatment of OCD.

Smoking Addiction treatment
BrainsWay’s latest treatment offering for short-term smoking cessation in adults, representing the first FDA clearance in the addiction space for any TMS device.

TMS Therapy

Our Treatments

Individuals looking for a treatment that works, and particularly treatment-resistant patients, can finally find relief thanks to BrainsWay Deep TMS:

View Our Treatments

Patients & Healthcare Providers

How does Deep TMS work?

BrainsWay has revolutionized the treatment of depression, OCD, and smoking addiction. With BrainsWay’s unique treatment, you can regain a sense of well-being and enjoy a better quality of life in just a few weeks.

It starts here.
Learn how it works

Patient Consultation for Deep TMS Treatment

Patients & Healthcare Providers

How do we help?

BrainsWay seeks to ensure that mental health providers, referral partners, and patients have the support necessary to achieve their goals.

We’re here for you.
Learn how we help you

Brainsway TMS

Clinically Proven Efficacy

From numerous studies to gaining FDA clearance and the European CE mark, BrainsWay’s safe and effective Deep TMS treatment is at the forefront of mental health treatments that are offering patients a brighter future.

Patient FAQs
Healthcare Professionals FAQs
Knowledge Center

Find A Deep TMS Provider Near You

With more than 800 providers, BrainsWay can provide the care you need.

Find a Provider

News & Events

See all the latest news, events and in the media BrainsWay has to offer and everything in-between.

July 23, 2024

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

BURLINGTON, Mass. and JERUSALEM, Israel, July 23, 2024 – BrainsWay Ltd. (NASDAQ & TASE: BWAY)...

July 2, 2024

CBS Describes Alternatives to Antidepressants that Won’t Cause Weight Gain

Dr. Aron Tendler, psychiatrist and chief medical officer at BrainsWay, highlighted the correlation between...

June 17, 2024

BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada

BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

Recent Articles

See all the latest mental health education articles and FAQs from BrainsWay.